TY - JOUR
T1 - Identification of amino acid sequences in fibrinogen γ-chain and tenascin C C-terminal domains critical for binding to integrin α(v)β3
AU - Yokoyama, Kenji
AU - Erickson, Harold P.
AU - Ikeda, Yasuo
AU - Takada, Yoshikazu
PY - 2000/6/2
Y1 - 2000/6/2
N2 - Integrin α(v)β3 recognizes fibrinogen γ and α(E) chain C-terminal domains (γC and α(E)C) but does not require the γC dodecapeptide sequence HHLGGAKQAGDV400-411 for binding to γC. We have localized the α(v)β3 binding sites in γC using γC-derived synthetic peptides. We found that two peptides GWTVFQKRLDGSV190-202 and GVYYQGGTYSKAS346-358 block the α(v)β3 binding to γC or α(E)C, block the a{v)β3-mediated clot retraction, and induce the ligand-induced binding site 2 (LIBS2) epitope in a{v)β3. Neither peptide affects fibrinogen binding to α(IIb)β3. Scrambled or inverted peptides were not effective. These results suggest that the two γC-derived peptides directly interact with α(v)β3 and specifically block a{v)β3-γC or α(E)C interaction. The two sequences are located next to each other in the γC crystal structure, although they are separate in the primary structure. Asp-199, Ser-201, Gln-350, Thr-353, Lys- 356, Ala-357, and Ser-358 residues are exposed to the surface. This suggests that the two sequences are part of α(v)β3 binding sites in fibrinogen γC domain. We also found that tenascin C C-terminal fibrinogen-like domain specifically binds to α(v)β3. Notably, a peptide WYRNCHRVNLMGRYGDNHSQGVNWFHWKG from this domain that includes the sequence corresponding to γC GVYYQGGTYSKAS346-358 specifically binds to α(v)β3, suggesting that fibrinogen and tenascin C C-terminal domains interact with α(v)β3 in a similar manner.
AB - Integrin α(v)β3 recognizes fibrinogen γ and α(E) chain C-terminal domains (γC and α(E)C) but does not require the γC dodecapeptide sequence HHLGGAKQAGDV400-411 for binding to γC. We have localized the α(v)β3 binding sites in γC using γC-derived synthetic peptides. We found that two peptides GWTVFQKRLDGSV190-202 and GVYYQGGTYSKAS346-358 block the α(v)β3 binding to γC or α(E)C, block the a{v)β3-mediated clot retraction, and induce the ligand-induced binding site 2 (LIBS2) epitope in a{v)β3. Neither peptide affects fibrinogen binding to α(IIb)β3. Scrambled or inverted peptides were not effective. These results suggest that the two γC-derived peptides directly interact with α(v)β3 and specifically block a{v)β3-γC or α(E)C interaction. The two sequences are located next to each other in the γC crystal structure, although they are separate in the primary structure. Asp-199, Ser-201, Gln-350, Thr-353, Lys- 356, Ala-357, and Ser-358 residues are exposed to the surface. This suggests that the two sequences are part of α(v)β3 binding sites in fibrinogen γC domain. We also found that tenascin C C-terminal fibrinogen-like domain specifically binds to α(v)β3. Notably, a peptide WYRNCHRVNLMGRYGDNHSQGVNWFHWKG from this domain that includes the sequence corresponding to γC GVYYQGGTYSKAS346-358 specifically binds to α(v)β3, suggesting that fibrinogen and tenascin C C-terminal domains interact with α(v)β3 in a similar manner.
UR - http://www.scopus.com/inward/record.url?scp=0034595969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034595969&partnerID=8YFLogxK
U2 - 10.1074/jbc.M000610200
DO - 10.1074/jbc.M000610200
M3 - Article
C2 - 10747940
AN - SCOPUS:0034595969
SN - 0021-9258
VL - 275
SP - 16891
EP - 16898
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 22
ER -